<DOC>
	<DOCNO>NCT03064035</DOCNO>
	<brief_summary>The goal study determine fix dose 4-factor prothrombin complex concentrate ( 4FPCC ) effective current standard care . 4FPCC used reverse effect warfarin patient emergent bleeding . The investigator hope study help doctor treat patient quick future . In addition , may cheaper patient hospital . This medication doctor would use reverse warfarin 's effect , low dose . Hypothesis : A fix dose 4FPCC comparable FDA-approved variable dose reversal warfarin-induced anticoagulation ( defined international normalize ratio [ INR ] ≤ 1.5 ) patient INR ≥2 experience emergent bleed require emergent surgery .</brief_summary>
	<brief_title>Fixed Versus Variable Dosing 4-factor Prothrombin Complex Concentrate Emergent Warfarin Reversal</brief_title>
	<detailed_description>Warfarin common oral anticoagulant utilized United States treatment prevention thromboembolic event condition . Although effective , major complication associate warfarin risk major bleed event . Incidence major bleed event long-term warfarin user 1.5 % 5.2 % per year , mortality exceed 13 % . Among patient intracranial bleed , mortality rate increase 46 % -55 % . In situation , imperative reverse pharmacologic effect warfarin quickly order minimize bleeding reduce risk death . Warfarin inhibit formation vitamin K-dependent clot factor II , VII , IX , X , proteins C S. An international normalized ratio ( INR ) commonly utilized laboratory test measure amount anticoagulation provide warfarin monitor throughout therapy . The INR standardize ratio utilize prothrombin time prevent variation institutional laboratory . Prothrombin time define time require plasma clot addition clot factor . A normal INR healthy adult range 0.8-1.2 . The majority patient chronic warfarin therapy target INR 2-3 . The optimal dose 4FPCC currently unknown despite multiple study evaluate different dose regimen . The FDA-approved dosing 25 50 IU factor IX per kilogram body weight , depend INR . It dose maximum 100 kilogram body weight . The FDA-approved variable dose algorithm follow : initial INR 2-3.9 : 25 IU/kg ( maximum dose 2500 IU ) , initial INR 4-6 : 35 IU/kg ( maximum dose 3500 IU ) , initial INR &gt; 6 : 50 IU/kg ( maximum dose 5000 IU ) . Exact dose 4FPCC administered may vary slightly calculate dos amount 4FPCC differs base vial utilize . By incorporate fix dose 1500 IU , present INR body weight may need determine prior administration . This may allow early administration prevent delay warfarin reversal patient emergent bleed . This research may determine whether fix dose effective reverse warfarin target INR le 1.5 compare FDA-approved variable dosing . In addition , low fixed-dose significantly reduce cost institution . Hypothesis : A fix dose 4FPCC comparable FDA-approved variable dose reversal warfarin-induced anticoagulation ( defined international normalize ratio [ INR ] ≤ 1.5 ) patient INR ≥2 experience emergent bleed require emergent surgery .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<mesh_term>Thrombin</mesh_term>
	<criteria>Chronic anticoagulation warfarin initial INR ≥2 Emergent bleeding ( i.e . intracranial hemorrhage , gastrointestinal hemorrhage , urgent invasive procedure , etc . ) urgent surgery require reversal INR ≤1.5 Younger 18 year age History heparininduced thrombocytopenia ( HIT ) Patients without initial postadministration INR read Patients initial INR &lt; 2 Pregnant patient Prisoners</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>125 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>